Geron Corporation · Menlo Park, CA United States (NASDAQ: GERN)
| 230 Constitution Dr. | Phone: 650-473-7700 |
| Menlo Park, CA | Fax: 650-473-7750 |
| 94025 | |
| United States | 
Map This Company |
Geron Corporation Rankings
More Companies in These Related Industries: Pharmaceutical Preparation MfgCompany Description
Geron is working to get important things into our thick heads -- more specifically, it is developing a compound able to penetrate the blood-brain barrier that otherwise keeps potentially valuable drugs out of the brain. The company's research and development is targeting viable therapies for cancer, injury, and degenerative diseases. One of the company's lead products in clinical trials is an hESC therapy (derived from human stem cells) called GRNOPC1 for spinal cord injury. Geron is also focused on anticancer drug candidate GRN163L, which inhibits telomerase, an enzyme that enables cancer cells to replicate indefinitely. Founded in 1992, Geron maintains facilities in California and Scotland.
Geron Corporation Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: GERN Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 175 |
Executives
28 executives listed for Geron Corporation's Menlo Park, CA location.
| Chairman | Hoyoung Huh | |
|---|---|---|
| President, Interim CEO, CFO, and Director | David Greenwood | |
| SVP and Chief Scientific Officer, Cell Therapies | Jane Lebkowski |